Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.
Valim V, Martins-Filho OA, Gouvea MDPG, Camacho LAB, Villela DAM, de Lima SMB, Azevedo AS, Neto LFP, Domingues CMAS, de Medeiros Junior NF, Moulaz IR, Dias LH, Miyamoto ST, Teixeira-Carvalho A, Mill JG; Half Dose ChAdOx Study Group. Valim V, et al. Among authors: gouvea mdpg. Front Immunol. 2022 Aug 29;13:966416. doi: 10.3389/fimmu.2022.966416. eCollection 2022. Front Immunol. 2022. PMID: 36105814 Free PMC article. Clinical Trial.
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
Valim V, Machado KLLL, Miyamoto ST, Pinto AD, Rocha PCM, Serrano EV, Dinis VG, Gouvêa SA, Dias JGF, Campi-Azevedo AC, Teixeira-Carvalho A, Peruhype-Magalhães V, da Costa-Rocha IA, de Lima SMB, Miranda EH, Trindade GF, Maia MLS, Gavi MBRO, da Silva LB, Duque RH, Gianordoli APE, Casagrande TZ, Oliveira KG, Moura BCDM, Nicole-Batista F, Rodrigues LC, Clemente TB, Magalhães ES, Bissoli MF, Gouvea MDPG, Pinto-Neto LFDS, Costa CZ, Giovelli RA, Brandão LR, Polito ETL, Koehlert IO, Borjaille BP, Pereira DB, Dias LH, Merlo DL, Genelhu LFF, Pretti FZ, Giacomin MDS, Burian APN, Fantinato FFST, Pileggi GS, da Mota LMH, Martins-Filho OA. Valim V, et al. Among authors: gouvea mdpg. Front Immunol. 2020 Jul 17;11:1382. doi: 10.3389/fimmu.2020.01382. eCollection 2020. Front Immunol. 2020. PMID: 32765496 Free PMC article.
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
da Costa-Rocha IA, Machado KLLL, Campi-Azevedo AC, Teixeira-Carvalho A, Peruhype-Magalhães V, de Lima SMB, Miranda EH, Trindade GF, Casagrande TZ, Miyamoto ST, Deotti SC, Barbosa RVR, Rocha PCM, Serrano EV, Dinis VG, Gouvêa SA, Gavi MBRO, da Silva LB, Duque RH, Gianordoli APE, Bissoli MF, Gouvea MDPG, Pinto-Neto LFDS, Burian APN, Fantinato FFST, Pileggi GS, da Mota LMH, Valim V, Martins-Filho OA. da Costa-Rocha IA, et al. Among authors: gouvea mdpg. Sci Rep. 2021 May 17;11(1):10431. doi: 10.1038/s41598-021-89770-8. Sci Rep. 2021. PMID: 34001945 Free PMC article.
Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
Casagrande TZ, Costa-Rocha IAD, Gavi MBRO, Miyamoto ST, Martins PC, Serrano ÉV, Dinis VG, Machado KLLL, Gouvea SA, Caser LC, Campi-Azevedo AC, Teixeira-Carvalho A, Peruhype-Magalhães V, Bissoli MF, Gouvea MDPG, Lima SMB, Miranda EH, Trindade GF, Lyra DGP, Burian APN, Neto LFDSP, da Mota LMH, Martins-Filho OA, Valim V. Casagrande TZ, et al. Among authors: gouvea mdpg. Vaccine. 2022 Jul 30;40(32):4580-4593. doi: 10.1016/j.vaccine.2022.05.071. Epub 2022 Jun 18. Vaccine. 2022. PMID: 35728990
Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence.
Gouvea MDPG, Moulaz IR, Gouveia TM, Lança KEM, Lacerda BSP, Thompson BP, Polese J, Lima MD, Ribeiro-Rodrigues R, Mill JG, Valim V. Gouvea MDPG, et al. Rev Soc Bras Med Trop. 2022 Oct 24;55:e01062022. doi: 10.1590/0037-8682-0106-2022. eCollection 2022. Rev Soc Bras Med Trop. 2022. PMID: 36287469 Free PMC article.
Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases.
Galvão-Lima LJ, de Medeiros Júnior NF, Jesus GS, Morais AHF, Caldeira-Silva GJP, Queiroz Dos Santos JP, Rocha M, Marques Dos Santos M, Freire PA, Silva RD, Gouvea MDPG, Neto LFP, Domingues CMAS, Teixeira-Carvalho A, Martins-Filho OA, Valim V, Valentim RAM. Galvão-Lima LJ, et al. Among authors: gouvea mdpg. IJID Reg. 2023 Sep 30;9:88-94. doi: 10.1016/j.ijregi.2023.09.007. eCollection 2023 Dec. IJID Reg. 2023. PMID: 37953882 Free PMC article.